Table 2: Pathological features of patients with CD5+ and CD5− de novo DLBCL (combined training and validation sets).
| Variables | CD5+ | CD5− | CD5+ vs. CD5− | CD5+ ABC | CD5− ABC | CD5+ ABC vs. CD5− ABC |
|---|---|---|---|---|---|---|
| N(%) | N(%) | N(%) | N(%) | |||
| Bcl-2 overexpression | ||||||
| < 70% | 12(25.5) | 369(47.2) | .0039 | 5(15.2) | 145(39.2) | .0076 |
| ≥ 70% | 35(74.5) | 412(52.8) | 28(84.8) | 225(60.8) | ||
| BCL2 gene | ||||||
| Normal | 31(83.8) | 520(78.4) | .13 | 19(79.2) | 248(84.3) | 0.38 |
| Translocation | 1(2.7) | 86(13) | 0(0) | 9(3.1) | ||
| Amplification or polysomy | 5(13.5) | 57(8.6) | 5(20.8) | 37(12.6) | ||
| MYC nonsilent CDS mutations | ||||||
| Mut | 1(2.6) | 97(17.5) | .04 | 0(0) | 39(15.2) | .034 |
| WT | 38(97.4) | 458(82.5) | 27(100) | 218(84.8) | ||
| CXCR4 expression | ||||||
| < 20% | 21(52.5) | 461(66) | .089 | 15(53.6) | 194(59.1) | .56 |
| ≥ 20% | 19(47.5) | 237(34) | 13(46.4) | 134(40.9) | ||
| GCET overexpression | ||||||
| < 50% | 40(85.1) | 577(70.8) | .044 | 31(93.9) | 339(87.8) | .40 |
| ≥ 50% | 7(14.9) | 238(29.2) | 2(6.1) | 47(12.2) | ||
| FOXP1 overexpression | ||||||
| < 60% | 13(27.7) | 352(43.2) | .047 | 4(12.1) | 78(20.1) | .36 |
| ≥ 60% | 34(72.3) | 463(56.8) | 29(87.9) | 310(79.9) | ||
| CD10 overexpression | ||||||
| < 40% | 34(59.6) | 518(63) | .67 | 28(84.8) | 375(95.9) | .017 |
| ≥ 40% | 23(40.4) | 304(37) | 5(15.2) | 16(4.1) | ||
| CD30 | ||||||
| Negative | 44(95.7) | 674(81.8) | .015 | 33(100) | 311(79.9) | .0016 |
| Positive | 2(4.3) | 150(18.2) | 0(0) | 78(20.1) | ||
| Blimp-1 expression | ||||||
| < 10% | 32(68.1) | 492(66.8) | 1.0 | 21(63.6) | 205(59.8) | .71 |
| ≥ 10% | 15(31.9) | 244(33.2) | 12(36.4) | 138(40.2) | ||
| pStat3 overexpression | ||||||
| < 50% | 25(61) | 611(85.3) | .0002 | 16(55.2) | 279(82.1) | .0014 |
| ≥ 50% | 16(39) | 105(14.7) | 13(44.8) | 61(17.9) | ||
| Cyclin D3 | ||||||
| Negative | 38(90.5) | 526(77.5) | .05 | 28(93.3) | 248(76.8) | .037 |
| Positive | 4(9.5) | 153(22.5) | 2(6.7) | 75(23.2) | ||
| p50 nuclear expression | ||||||
| Negative | 23(53.5) | 337(45.4) | .35 | 17(54.8) | 129(36.6) | .05 |
| Positive | 20(46.5) | 405(54.6) | 14(45.2) | 223(63.4) | ||
| p52 nuclear expression | ||||||
| Negative | 36(80) | 537(76) | .59 | 27(84.4) | 254(76.3) | .38 |
| Positive | 9(20) | 170(24) | 5(15.6) | 79(23.7) | ||
| p65 nuclear expression | ||||||
| Negative | 16(36.4) | 376(49.2) | .12 | 11(35.5) | 194(52.9) | .09 |
| Positive | 28(63.6) | 389(50.8) | 20(64.5) | 173(47.1) | ||
| RelB nuclear expression | ||||||
| Negative | 25(96.2) | 378(85.3) | .15 | 19(95) | 172(83.5) | .33 |
| Positive | 1(3.8) | 65(14.7) | 1(5) | 34(16.5) | ||
| c-Rel nuclear expression | ||||||
| Negative | 23(56.1) | 521(72.3) | .033 | 18(62.1) | 255(74.6) | .19 |
| Positive | 18(43.9) | 200(27.7) | 11(37.9) | 87(25.4) | ||
| SSBP2 expression | ||||||
| ≤ 5% | 36(76.6) | 283(37.7) | < .0001 | 27(81.8) | 182(52.6) | .0015 |
| > 5% | 11(23.4) | 468(62.3) | 6(18.4) | 164(47.4) | ||
Note: LDH, serum lactate dehydrogenase; IPI, International Prognostic Index; BM, bone marrow; COO, cell-of-origin; GCB, germinal center B-like; ABC, activated B-cell like. Due to tissue exhaustion, immunohistochemical staining analysis for some markers was not successful in few cases.